Membrane perturbations induced by new analogs of neocryptolepine

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 9, 2012, Pages 1432-1439

  Jaromin, Anna ^a   Korycińska, Mariola ^a   Piȩtka Ottlik, Magdalena ^b   Musiał, Witold ^c   Peczyńska Czoch, Wanda ^b   Kaczmarek, Łukasz ^d   Kozubek, Arkadiusz ^a  

^a UNIVERSITY OF WROC AW   (Poland)

^b WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

^d INDUSTRIAL CHEMISTRY RESEARCH INSTITUTE   (Poland)

Author keywords

Acetylcholinesterase activity; Erythrocyte ghost; Hemolysis; Indoloquinoline; Neocryptolepine; Partition coefficient

Indexed keywords

2 (DIMETHYLAMINO) N (5,11 DIMETHYL 5H INDOLO[2,3 B]QUINOL 9 YL)ACETAMIDE; 5,11 DIMETHYL 5H INDOLO[2,3 B]QUINOLINE; ACETYLCHOLINESTERASE; CARBOXYFLUORESCEIN; CRYPTOLEPINE DERIVATIVE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; DNA TOPOISOMERASE (ATP HYDROLYSING); INDOLOQUINOLINE DERIVATIVE; LIPOSOME; N,N DIMETHYL 2 (5,11 DIMETHYL 5H INDOLO[2,3 B]QUINOL 2 YLOXY)ETHYLAMINE; OCTANOL; UNCLASSIFIED DRUG; WATER;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; DRUG STRUCTURE; ERYTHROCYTE GHOST; HEMOLYSIS; HYDROPHOBICITY; IN VITRO STUDY; LIPID BILAYER; MEMBRANE BINDING; MEMBRANE DAMAGE; MEMBRANE STRUCTURE; NONHUMAN; PARTITION COEFFICIENT;

EID: 84866005072     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b110671     Document Type: Article

References (58)

1. Lavrado J, Moreira R, Paulo A. Indoloquinolines as scaffolds for drug discovery. Curr. Med. Chem., 17, 2348-2370 (2010).
2. Sofowora A. Medicinal Plants and Traditional Medicine in Africa. John Wiley & Sons, Chichester, pp. 221-223 (1982).
3. Oliver-Bever B. Medicinal Plants in Tropical West Africa. Cambridge University Press, Cambridge, pp. 18, 41, 131, 205 (1986).
4. Paulo A, Pimentel M, Viegas S, Pires I, Duarte A, Cabrita J, Gomes ET. Cryptolepis sanguinolenta activity against diarrhoeal bacteria. J. Ethnopharmacol., 44, 73-77 (1994a).
5. Paulo A, Duarte A, Gomes ET. In vitro antibacterial screening of Cryptolepis sanguinolenta alkaloids. J. Ethnopharmacol., 44, 127-130 (1994b).
6. Sawer IK, Berry MI, Brown MW, Ford JL. The effect of cryptolepine on the morphology and survival of Escherichia coli, Candida albicans and Saccharomyces cerevisiae. J. Appl. Bacteriol., 79, 314-321 (1995).
7. Cimanga K, De Bruyne T, Pieters L, Totte J, Tona L, Kambu K, van den Berghe D, Vlietinck AJ. Antibacterial and antifungal activities of neocryptolepine, biscryptolepine and cryptoquinoline, alkaloids isolated from Cryptolepis sanguinolenta. Phytomedicine, 5, 209-214 (1998).
8. Bierer DE, Fort DM, Mendez CD, Luo J, Imbach PA, Dubenko LG, Jolad SD, Gerber RE, Litvak J, Lu Q, Zhang P, Reed MJ, Waldeck N, Bruening RC, Noamesi BK, Hector RF, Carlson TJ, King SR. Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities. J. Med. Chem., 41, 894-901 (1998).
9. Luo J, Fort DM, Carlson TJ, Noamesi BK, nii-Amon-Kotei D, King SR, Tsai J, Quan J, Hobensack C, Lapresca P, Waldeck N, Mendez CD, Jolad SD, Bierer DE, Reaven GM. Cryptolepis sanguinolenta: an ethnobotanical approach to drug discovery and the isolation of a potentially useful new antihyperglycaemic agent. Diabet. Med., 15, 367-374 (1998).
10. Bamgbose SOA, Noamesi BK. Studies on cryptolepine. II: Inhibition of carrageenan induced oedema by cryptolepine. Planta Med., 41, 392-396 (1981).
11. Olajide OA, Ajayi AM, Wright CW. Anti-inflammatory properties of cryptolepine. Phytother. Res., 23, 1421-1425 (2009).
12. Kirby GC, Paine A, Warhurst DC, Noamesi BK, Phillipson JD. In vitro and in vivo antimalarial activity of cryptolepine, a plant-derived indoloquinoline. Phytother. Res., 9, 359-363 (1995).
13. Grellier P, Ramiaramanana L, Milleriox V, Deharo E, Shrevel J, Frappier F, Trigalo F, Bodo B, Pousset JL. Antimalarial activity of cryptolepine and isocryptolepine, alkaloids isolated from Cryptolepis sanguinolenta. Phytother. Res., 10, 317-321 (1996).
14. Cimanga K, De Bruyne T, Pieters L, Vlietinck AJ, Turger CA. In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta. J. Nat. Prod., 60, 688-691 (1997).
15. Paulo A, Gomes ET, Steele J, Warhurst DC, Houghton PJ. Antiplasmodial activity of Cryptolepis sanguinolenta alkaloids from leaves and roots. Planta Med., 66, 30-34 (2000).
16. Bugyei KA, Boye GL, Addy ME. Clinical efficacy of a tea-bag formulation of Cryptolepis sanguinolenta root in the treatment of acute uncomplicated falciparum malaria. Ghana Med. J., 44, 3-9 (2010).
17. Peczyńska-Czoch W, Pognan F, Kaczmarek Ł, Boratyński J. Synthesis and structure-activity relationship of methyl-substituted indolo[2,3-b]quinolines: novel cytotoxic, DNA topoisomerase II inhibitors. J. Med. Chem., 37, 3503-3510 (1994).
18. Kaczmarek Ł, Peczyńska-Czoch W, Osiadacz J, Mordarski M, Sokalski WA, Boratyński J, Marcinkowska E, Glazman-Kuśnierczyk H, Radzikowski C. Synthesis, and cytotoxic activity of some novel indolo[2,3-b]quinoline derivatives: DNA topoisomerase II inhibitors. Bioorg. Med. Chem., 7, 2457-2464 (1999).
19. Arzel E, Rocca P, Grellier P, Labaeïd M, Frappier F, Guéritte F, Gaspard C, Marsais F, Godard A, Quéguiner G. New synthesis of benzo-delta-carbolines, cryptolepines, and their salts: in vitro cytotoxic, antiplasmodial, and antitrypanosomal activities of delta-carbolines, benzo-delta-carbolines, and cryptolepines. J. Med. Chem., 44, 949-960 (2001).
20. Wright CW, Addae-Kyereme J, Breen AG, Brown JE, Cox MF, Croft SL, Gökçek Y, Kendrick H, Phillips RM, Pollet PL. Synthesis and evaluation of cryptolepine analogues for their potential as new antimalarial agents. J. Med. Chem., 44, 3187-3194 (2001).
21. Jonckers THM, van Miert S, Cimanga K, Bailly C, Colson P, De Pauw-Gillet MC, van den Heuvel H, Claeys M, Lemière F, Esmans EL, Rozenski J, Quirijnen L, Maes L, Dommisse R, Lemière GLF, Vlietinck A, Pieters L. Synthesis, cytotoxicity, and antiplasmodial and antitrypanosomal activity of new neocryptolepine derivatives. J. Med. Chem., 45, 3497-3508 (2002).
22. Onyeibor O, Croft SL, Dodson HI, Feiz-Haddad M, Kendrick H, Millington NJ, Parapini S, Phillips RM, Seville S, Shnyder SD, Taramelli D, Wright CW. Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action. J. Med. Chem., 48, 2701-2709 (2005).
23. Zhu XY, Mardenborough LG, Li S, Khan A, Zhang W, Fan P, Jacob M, Khan S, Walker L, Ablordeppey SY. Synthesis and evaluation of isosteres of N-methyl indolo[3,2-b]-quinoline (cryptolepine) as new antiinfective agents. Bioorg. Med. Chem., 15, 686-695 (2007).
24. Seville S, Phillips RM, Shnyder SD, Wright CW. Synthesis of cryptolepine analogues as potential bioreducible anticancer agents. Bioorg. Med. Chem., 15, 6353-6360 (2007).
25. Yang SH, Chien CM, Su JC, Chen YL, Chang LS, Lin SR. Novel indoloquinoline derivative, IQDMA, inhibits STAT5 signaling associated with apoptosis in K562 cells. J. Biochem. Mol. Toxicol., 22, 396-404 (2008).
26. Van Baelen G, Hostyn S, Dhooghe L, Tapolcsányi P, Mátyus P, Lemière G, Dommisse R, Kaiser M, Brun R, Cos P, Maes L, Hajós G, Riedl Z, Nagy I, Maes BU, Pieters L. Structure-activity relationship of antiparasitic and cytotoxic indoloquinoline alkaloids, and their tricyclic and bicyclic analogues. Bioorg. Med. Chem., 17, 7209-7217 (2009).
27. Riechert-Krause F, Eick A, Grünert R, Bednarski PJ, Weisz K. In vitro anticancer activity and evaluation of DNA duplex binding affinity of phenyl-substituted indoloquinolines. Bioorg. Med. Chem. Lett., 21, 2380-2383 (2011).
28. Kaczmarek Ł, Balicki R, Nantka-Namirski P, Peczyńska-Czoch W, Mordarski M. Cancerostatics, VI. Synthesis and antineoplastic properties of some benzo-iso-alpha-carbolines. Arch. Pharm. (Weinheim), 321, 463-467 (1988).
29. Pognan F, Saucier JM, Paoletti C, Kaczmarek L, Nantka-Namirski P, Mordarski M, Peczynska-Czoch W. A carboline derivative as a novel mammalian DNA topoisomerase II targeting agent. Biochem. Pharmacol., 44, 2149-2155 (1992).
30. Kaczmarek Ł, Peczyńska-Czoch W, Opolski A, Wietrzyk J, Marcinkowska E, Boratyński J, Osiadacz J. Methoxy- and methyl-, methoxy-5,6,11-trimethyl-6H-indolo[2,3-b]quinolinium derivatives as novel cytotoxic agents and DNA topoisomerase II inhibitors. Anticancer Res., 18 (4C), 3133-3138 (1998).
31. Kaczmarek Ł, Luniewski W, Zagrodzki B, Godlewska J, Osiadacz J, Wietrzyk J, Opolski A, Peczyńska-Czoch W. Synthesis of 6-substituted 6H-indolo[2,3-b]quinolines as novel cytotoxic agents and topoisomerase II inhibitors. Acta Pol. Pharm., 59, 199-207 (2002).
32. Humeniuk R, Kaczmarek Ł, Peczyńska-Czoch W, Marcinkowska E. Cytotoxicity and cell cycle effects of novel indolo[2,3-b]quinoline derivatives. Oncol. Res., 13, 269-277 (2003).
33. Godlewska J, Luniewski W, Zagrodzki B, Kaczmarek Ł, Bielawska-Pohl A, Dus D, Wietrzyk J, Opolski A, Siwko M, Jaromin A, Jakubiak A, Kozubek A, Peczyñska-Czoch W. Biological evaluation of omega-(dialkylamino)alkyl derivatives of 6H-indolo[2,3-b]quinoline - novel cytotoxic DNA topoisomerase II inhibitors. Anticancer Res., 25, 2857-2868 (2005).
34. Osiadacz J, Majka J, Czarnecki K, Peczyńska-Czoch W, Zakrzewska-Czerwińska J, Kaczmarek Ł, Sokalski WA. Sequence-selectivity of 5,11-dimethyl-5H-indolo[2,3-b]quinoline binding to DNA. Footprinting and molecular modeling studies. Bioorg. Med. Chem., 8, 937-943 (2000).
35. Stasiuk M, Jaromin A, Kozubek A. The effect of merulinic acid on biomembranes. Biochim. Biophys. Acta, 1667, 215-221 (2004).
36. Dodge JT, Mitchell C, Hanahan DJ. The preparation and chemical characteristics of hemoglobin-free ghosts of human erythrocytes. Arch. Biochem. Biophys., 100, 119-130 (1963).
37. Rouser G, Siakotos AN, Fleischer S. Quantitative analysis of phospholipids by thin-layer chromatography and phosphorus analysis of spots. Lipids, 1, 85-86 (1966).
38. Pinto LMA, Yokaichiya DK, Fraceto LF, de Paula E. Interaction of benzocaine with model membranes. Biophys. Chem., 87, 213-223 (2000).
39. Cheng HY, Randall CS, Holl WW, Constantinides PP, Yue TL, Feuerstein GZ. Carvedilol-liposome interaction: evidence for strong association with the hydrophobic region of the lipid bilayers. Biochim. Biophys. Acta, 1284, 20-28 (1996).
40. Jaromin A, Kozubek A, Suchoszek-Lukaniuk K, Malicka-Blaszkiewicz M, Peczynska-Czoch W, Kaczmarek Ł. Liposomal formulation of DIMIQ, potential antitumor indolo[2,3-b]quinoline agent and its cytotoxicity on hepatoma Morris 5123 cells. Drug Deliv., 15, 49-56 (2008).
41. Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol., 7, 88-95 (1961).
42. El Mashak EM, Paoletti C, Tocanne JF. Interactions between ellipticine and some derivatives and phospholipids in model membranes. FEBS Lett., 107, 155-159 (1979).
43. Sureau F, Moreau F, Millot JM, Manfait M, Allard B, Aubard J, Schwaller MA. Microspectrofluorometry of the protonation state of ellipticine, an antitumor alkaloid, in single cells. Biophys. J., 65, 1767-1774 (1993).
44. Terce F, Tocanne JF, Laneelle G. Interactions of ellipticine with model or natural membranes. A spectrophotometric study. Eur. J. Biochem., 125, 203-207 (1982).
45. Malheiros SVP, Pinto LMA, Gottardo L, Yokaichiya DK, Fraceto LF, Meirelles NC, de Paula E. A new look at the hemolytic effect of local anesthetics, considering their real membrane/water partitioning at pH 7.4. Biophys. Chem., 110, 213-221 (2004).
46. Malheiros SVP, de Paula E, Meirelles NC. Contribution of trifluoperazine/lipid ratio and drug ionization to hemolysis. Biochim. Biophys. Acta, 1373, 332-340 (1998).
47. Malheiros SVP, Meirelles NC, de Paula E. Pathways involved in trifluoperazine-, dibucaine- and praziquantel-induced hemolysis. Biophys. Chem., 83, 89-100 (2000).
48. Ahyayauch H, Goñi FM, Bennouna M. Interaction of electrically neutral and cationic forms of imipramine with liposome and erythrocyte membranes. Int. J. Pharm., 279, 51-58 (2004).
49. Cruz Silva MM, Madeira VMC, Almeida LM, Custódio JBA. Hemolysis of human erythrocytes induced by tamoxifen is related to disruption of membrane structure. Biochim. Biophys. Acta, 1464, 49-61 (2000).
50. Cruz Silva MM, Madeira VMC, Almeida LM, Custódio JBA. Hydroxytamoxifen interaction with human erythrocyte membrane and induction of permeabilization and subsequent hemolysis. Toxicol. In Vitro, 15, 615-622 (2001).
51. Hou SZ, Su ZR, Chen SX, Ye MR, Huang S, Liu L, Zhou H, Lai XP. Role of the interaction between puerarin and the erythrocyte membrane in puerarin-induced hemolysis. Chem. Biol. Interact., 192, 184-192 (2011).
52. Lee IP. A possible mechanism of ellipticine-induced hemolysis. J. Pharmacol. Exp. Ther., 196, 525-535 (1976).
53. Godlewska J, Peczynska-Czoch W, Kaczmarek Ł, Wietrzyk J, Nasulewicz A, Kozubek A, Gubernator J, Opolski A. The 3rd International Conference on Tumor Microenvironment: Progression, Therapy and Prevention in Prague, Medimond, Bologna. pp. 109-113 (2004).
54. Boschetti N, Brodbeck U. The membrane anchor of mammalian brain acetylcholinesterase consists of a single glycosylated protein of 22 kDa. FEBS Lett., 380, 133-136 (1996).
55. Morton CL, Wadkins RM, Danks MK, Potter PM. The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. Cancer Res., 59, 1458-1463 (1999).
56. Harel M, Hyatt JL, Brumshtein B, Morton CL, Wadkins RM, Silman I, Sussman JL, Potter PM. The 3D structure of the anticancer prodrug CPT-11 with Torpedo californica acetylcholinesterase rationalizes its inhibitory action on AChE and its hydrolysis by butyrylcholinesterase and carboxylesterase. Chem. Biol. Interact., 157-158, 153-157 (2005).
57. Mardenborough LG, Zhu XY, Fan P, Jacob MR, Khan SI, Walker LA, Ablordeppey SY. Identification of bis-quindolines as new antiinfective agents. Bioorg. Med. Chem., 13, 3955-3963 (2005).
58. Tõugu V, Kesvatera T. Comparison of salt effects on the reactions of acetylcholinesterase with cationic and anionic inhibitors. Biochim. Biophys. Acta, 1544, 189-195 (2001).